Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized trial investigating the role of FOLFOX-4 [fluorouracil + fluorouracil + folinic acid] regimen duration (3 versus 6 months) and bevacizumab as adjuvant therapy for patients with stage II/III colon cancer

Next Previous
Search
Trial Profile

A randomized trial investigating the role of FOLFOX-4 [fluorouracil + fluorouracil + folinic acid] regimen duration (3 versus 6 months) and bevacizumab as adjuvant therapy for patients with stage II/III colon cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jul 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Oxaliplatin (Primary) ; Bevacizumab
  • Indications Adenocarcinoma; Colon cancer
  • Focus Therapeutic Use
  • Acronyms TOSCA

    • Most Recent Events

    • 08 Jun 2021 Results from 6 randomised trials NCT00749450, NCT00646607, NCT01150045, NCT00958737) in the IDEA database used to compare characteristics, tx adherence, and adverse events presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
    • 18 Mar 2021 Results (n=2360) of post hoc analysis published in the European Journal of Cancer
    • 12 Oct 2020 Results published in the Annals of Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top